GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Cash Flow from Financing

Pharos IBio Co (XKRX:388870) Cash Flow from Financing : ₩-31.48 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2024, Pharos IBio Co paid ₩0.00 Mil more to buy back shares than it received from issuing new shares. It received ₩0.00 Mil from issuing more debt. It paid ₩0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ₩0.00 Mil from paying cash dividends to shareholders. It received ₩132.12 Mil on other financial activities. In all, Pharos IBio Co earned ₩132.12 Mil on financial activities for the three months ended in Dec. 2024.


Pharos IBio Co Cash Flow from Financing Historical Data

The historical data trend for Pharos IBio Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Cash Flow from Financing Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 15,906.21 17,634.88 -271.11 18,805.50 -31.48

Pharos IBio Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,168.69 -43.90 -39.90 -39.90 92.22

Pharos IBio Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Pharos IBio Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Pharos IBio Co's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-31.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co  (XKRX:388870) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Pharos IBio Co's issuance of stock for the three months ended in Dec. 2024 was ₩0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Pharos IBio Co's repurchase of stock for the three months ended in Dec. 2024 was ₩0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Pharos IBio Co's net issuance of debt for the three months ended in Dec. 2024 was ₩0.00 Mil. Pharos IBio Co received ₩0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Pharos IBio Co's net issuance of preferred for the three months ended in Dec. 2024 was ₩0.00 Mil. Pharos IBio Co paid ₩0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Pharos IBio Co's cash flow for dividends for the three months ended in Dec. 2024 was ₩0.00 Mil. Pharos IBio Co received ₩0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Pharos IBio Co's other financing for the three months ended in Dec. 2024 was ₩132.12 Mil. Pharos IBio Co received ₩132.12 Mil on other financial activities.


Pharos IBio Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines